Trends in the use of thyroid diagnostics and treatments between 2008 and 2019 in Germany

Arulmani Thiyagarajan, Niklas Koenen, Till Ittermann, Henry Völzke, Ulrike HaugScientific 2024 · DOI

TL;DR

This study analyzed German health insurance claims data from 2008-2019 to track trends in thyroid diagnostics and treatments. While clinically significant thyroid disorders appear to be declining, the use of TSH measurements and levothyroxine prescriptions has significantly increased, suggesting potential overuse of diagnostics and overtreatment, particularly in women.

What Problem Does This Paper Address?

Following a successful national program to combat iodine deficiency in Germany in the 1990s, which led to a decline in thyroid disorders, researchers observed an apparent increase in thyroid hormone use based on aggregated drug dispensation data. This created a discrepancy: if thyroid disorders were declining, why was thyroid hormone use rising? The paper aims to systematically investigate this by examining trends in both diagnostic procedures and treatments for thyroid conditions across Germany between 2008 and 2019, using a large, representative dataset. The goal is to understand if this rise in hormone use is justified by actual disease prevalence or if it points to overdiagnosis and overtreatment.

Methods

The researchers utilized the German Pharmacoepidemiological Research Database (GePaRD), a large claims database covering approximately 20% of the German population. They conducted cross-sectional analyses for each year from 2008 to 2019. The study focused on the annual prevalence of specific thyroid diagnostic procedures (TSH measurement, ultrasound, scintiscan, biopsy) and treatments (levothyroxine, iodine, thionamides, thyroidectomy, radioiodine therapy). Prevalence was calculated per 1,000 persons, stratified by age and sex, and age-standardized using the German population distribution in 2019. They also analyzed the frequency of TSH measurements per person and explored correlations between the use of diagnostics/treatments and healthcare utilization.

Datasets

The primary dataset used was the German Pharmacoepidemiological Research Database (GePaRD). This database contains claims data from four statutory health insurance providers, covering approximately 25 million individuals and representing about 20% of the general German population. The data includes demographic information, prescription drug dispensations, and outpatient/inpatient services and diagnoses, coded using German uniform assessment standards (EBM), operations and procedures codes (OPS), and the Anatomic Therapeutic Chemical (ATC) classification.

Key Insights and Ideas

  • Divergent Trends: A key finding is the divergence between the apparent decline in clinically significant thyroid disorders and the simultaneous rise in TSH testing and levothyroxine prescriptions. This suggests that the increase in hormone use might not be directly driven by an increase in disease prevalence.
  • Potential Overdiagnosis/Overtreatment: The substantial increase in TSH measurements and levothyroxine use, especially when not clearly linked to rising disease rates, raises concerns about overdiagnosis and overtreatment. This is particularly noted in the discussion section.
  • Sex Differences: Women consistently show higher prevalences for most thyroid diagnostics and treatments compared to men, often two to four times higher. The significant increase in TSH testing and levothyroxine use was also observed in both sexes, but the implications for women warrant further investigation.
  • Age and Healthcare Utilization: The use of thyroid diagnostics and treatments generally increases with age and shows a positive correlation with healthcare utilization, suggesting that individuals with higher overall healthcare needs are more likely to undergo these procedures.
  • Declining Use of Other Treatments: While TSH testing and levothyroxine use increased, the use of other treatments like thionamides, iodine supplements, thyroidectomy, and radioiodine therapy generally decreased, aligning with the expected outcome of improved iodine status.

Key Results

  • TSH Measurement: Age-standardized prevalence of TSH measurement increased by 36% in males (from 165 to 225 per 1,000) and 24% in females (from 295 to 367 per 1,000) between 2008 and 2019.
  • Levothyroxine Use: The prevalence of levothyroxine use increased by approximately 31% in both males (from 36 to 47 per 1,000) and females (from 134 to 175 per 1,000) during the same period.
  • Other Diagnostics: Thyroid ultrasound use showed no clear time trend. Scintiscan use decreased by 42% in males and 43% in females, and biopsy use decreased by 42% in males and 34% in females.
  • Other Treatments: Thionamide use, iodine use, thyroidectomy, and radioiodine therapy all showed decreasing trends.
  • Gender Disparity: Prevalence of all considered thyroid diagnostic procedures and treatments was markedly higher in females than in males.

Limitations and Future Work

  • Limitations:
    • Claims data limitations: The study relies on claims data, which may not capture all medications dispensed in hospitals. However, the authors note that most thyroid medications are prescribed outpatient.
  • Lack of indication information: Claims data do not provide the reason for a diagnostic test or treatment (e.g., routine screening, monitoring, follow-up), making it difficult to definitively ascertain overuse.
  • No clinical examination data: The study cannot directly link diagnostic use to clinical findings or patient journeys.
  • Future Work:
    • Longitudinal analysis: The authors plan a next step involving longitudinal analysis of patient journeys at an individual level to better understand trends and potential overuse.
  • Pregnancy-specific analysis: An analysis focusing on the use of thyroid diagnostics and treatment before and during pregnancy is also planned.
  • Further investigation into overuse: The study strongly suggests further investigation into the potential overuse of diagnostics and overtreatment, particularly given the observed trends and sex differences.

Summary updated

Abstract

Following implementation of a national prevention program against iodine deficiency-related disorders in 1993 in Germany, the prevalence of thyroid disorders declined, but aggregated drug dispensation data suggested a recent increase in thyroid hormone use. We aimed to systematically investigate trends in the use of thyroid diagnostic and treatment measures between 2008 and 2019 in Germany. Using the GePaRD database (claims data from ~ 20% of the German population), we determined the annual age-specific and age-standardized prevalence of the use of thyroid diagnostics (thyroid-stimulating hormone (TSH) measurement, thyroid ultrasound, scintiscan, biopsy) and treatment (medication, surgery, radioiodine therapy) from 2008 to 2019 stratified by sex. Between 2008 and 2019, the age-standardized prevalence of TSH measurement increased by 44% in males (from 165 to 238 per 1,000 persons) and by 31% in females (from 134 to 176 per 1,000). The prevalence of thyroid ultrasound use showed no clear time trend, while there was a decrease in the prevalence of scintiscan use (males/females: decrease by 42/43%) and biopsy (males/females: decrease by 42/34%). The prevalence of levothyroxine use increased by ~ 31% both in males (from 36 to 47 per 1,000) and females (from 134 to 175 per 1,000), while the prevalence of thionamide use, iodine use, thyroidectomy, and radioiodine therapy decreased. Our study suggests a continued decline in the prevalence of clinically significant thyroid disorders between 2008 and 2019. The substantial increase in the prevalence of TSH measurement and levothyroxine use during this time period might indicate overuse of diagnostics and overtreatment, warranting further investigation.
BibTeX
@inproceedings{thiyagarajan2024trends,
  author = {Arulmani Thiyagarajan and Niklas Koenen and Till Ittermann and Henry Völzke and Ulrike Haug},
  title = {{Trends in the use of thyroid diagnostics and treatments between 2008 and 2019 in Germany}},
  booktitle = {Scientific},
  year = {2024},
  doi = {10.1038/s41598-024-77896-4},
}
Figure